(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 December 2014 (24.12.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/205365 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *C07K 16/28* (2006.01)

(21) International Application Number:
PCT/US2014/043440

(22) International Filing Date:
20 June 2014 (20.06.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/837,912 21 June 2013 (21.06.2013) US
14305670.3 7 May 2014 (07.05.2014) EP

(71) Applicants: **SANOFI** [FR/FR]; 54 Rue La Boetie, F-75008 Paris (FR). **REGENERON PHARMACEUTICALS, INC.** [US/US]; 77 Old Saw Mill River Road, Tarrytown, NY 10591 (US).

(72) Inventors: **MANNENT, Leda**; c/o Sanofi, 54 Rue La Boetie, F-75008 Paris (FR). **GIANLUCA, Pirozzi**; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-505A, Bridgewater, NJ 08807 (US). **RADIN, Allen**; c/o Regeneron Pharmaceuticals, Inc., 77 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **GANDHI, Namita, A.**; c/o Regeneron Pharmaceuticals, Inc., 77 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **EVANS, Robert**; C/o Regenron Pharmaceuticals, Inc., 77 Old Saw Mill River Road, Tarrytown, NY 10591 (US).

(74) Agents: **VELEMA, James H.** et al.; Lathrop & Gage LLP, 28 State Street, Suite 0700, Boston, MA 02109 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: METHODS FOR TREATING NASAL POLYPOSIS BY ADMINISTERING AN IL-4R ANTAGONIST




FIG. 1

(57) Abstract: The present invention provides methods for treating nasal polyposis. The methods include administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody or antigen binding fragment thereof.

WO 2014/205365 A1